AB-ARS
AI-based antibody candidate discovery platform
Platform · Cloud SaaSCompany source
Company profile
About Syntekabio
Syntekabio is a South Korean biotechnology company that leverages artificial intelligence, big data, and supercomputing to accelerate drug discovery and development. The company operates Korea's only AI Bio Supercomputing Center and has developed multiple proprietary AI platforms including SM-ARS for small-molecule drug discovery, AB-ARS for antibody candidate discovery, NEO-ARS for neoantigen discovery and cancer vaccine design, and DEEPMATCHER for protein-compound interaction prediction. Syntekabio's technology stack combines language models with virtual screening capabilities to enable faster, more precise innovation across multiple therapeutic modalities. The company serves pharmaceutical companies, biotech firms, and research institutions globally, offering AI-powered solutions that claim to accelerate drug discovery by 3x compared to traditional methods. With over 30 patents and 30 global partnerships, Syntekabio has established itself as a significant player in the AI drug discovery space. The company generates revenue through platform licensing, collaborative research agreements, and its data center operations. Recent milestones include generating over 1 billion KRW in revenue from its DeepMatcher platform in the first half of 2025 and expanding into next-generation markets with antibody optimization and cancer vaccine platforms.
Company description Syntekabio official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Syntekabio?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer
- Immunotherapy targets
- Various therapeutic areas via small molecule and antibody discovery
Who it serves
- Biotech
- Pharma
- Research institutions
Deployment & integration
Api Only · Cloud Saas deployment with recorded integration context.
Geographic context
MarketsGlobal markets · South Korea
Company sourceOfficial website
Company milestones
Platform expansion
Generated 1.2 billion KRW revenue in first half of 2025 with over 1 billion from DeepMatcher platform; received patent registration for eco-friendly termite-inspired data center design; expanding into next-generation markets with antibody optimization and cancer vaccine discovery platforms; targeting accelerated revenue growth with next-gen platforms
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Butler
Rapid cloud-based analysis of thousands of human genomes
Platform · Cloud SaaSCompany source
DEEPMATCHER
Language model for protein-compound interaction prediction
Model · Api OnlyCompany source
LM-VS
Language Model-based Virtual Screening platform
Platform · Cloud SaaSCompany source
NEO-ARS
AI-based neoantigen discovery and cancer vaccine design platform
Platform · Cloud SaaSCompany source
SM-ARS
AI-based small-molecule drug discovery platform
Platform · Cloud SaaSCompany source
STB Cloud
Cloud-based infrastructure for AI drug discovery
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Machine learning driven LD50 prediction for cancer risk assessment using modern molecular language models.Frontiers in oncology · Jan 1, 2026
Correction to: Nitrosylation of β2-Tubulin Promotes Microtubule Disassembly and Differentiated Cardiomyocyte Beating in Ischemic Mice.Tissue engineering and regenerative medicine · Dec 1, 2023
Nitrosylation of β2-Tubulin Promotes Microtubule Disassembly and Differentiated Cardiomyocyte Beating in Ischemic Mice.Tissue engineering and regenerative medicine · Oct 1, 2023
RDscan: A New Method for Improving Germline and Somatic Variant Calling Based on Read Depth Distribution.Journal of computational biology : a journal of computational molecular cell biology · Sep 1, 2022
Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer.Scientific reports · Feb 21, 2022
Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.Oncoimmunology · Jan 1, 2021
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
3x acceleration in drug discovery
Compared to traditional drug discovery methods
1.2 billion KRW revenue in H1 2025
Over 1 billion KRW from DeepMatcher platform alone
2 billion KRW expected annual revenue
From patented data center system
DeepMatcher platform customers
Protein-compound interaction prediction for drug discovery
Over 1.0 billion KRW in revenue generated in first half of 2025
Multiple pharmaceutical partners
AI-powered drug discovery acceleration across small molecules, antibodies, and cancer vaccines
3x acceleration in drug discovery process
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Syntekabio
Recent articles published on Syntekabio's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.